These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30906878)

  • 1. An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.
    Baron M; Kahaleh B; Bernstein EJ; Chung L; Clements PJ; Denton C; Domsic RT; Ferdowsi N; Foeldvari I; Frech T; Gordon JK; Hudson M; Johnson SR; Khanna D; McMahan Z; Merkel PA; Narain S; Nikpour M; Pauling JD; Ross L; Valenzuela Vergara AM; Vacca A
    J Scleroderma Relat Disord; 2019 Feb; 4(1):17-27. PubMed ID: 30906878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index.
    Ross L; Hansen D; Proudman S; Khanna D; Herrick AL; Stevens W; ; ; Baron M; Nikpour M;
    Arthritis Rheumatol; 2024 Jun; ():. PubMed ID: 38937146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
    Ferdowsi N; Huq M; Stevens W; Hudson M; Wang M; Tay T; Burchell JL; Mancuso S; Rabusa C; Sundararajan V; Prior D; Proudman SM; Baron M; Nikpour M; ;
    Ann Rheum Dis; 2019 Jun; 78(6):807-816. PubMed ID: 30928903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.
    Lee TH; Lee JS; Park S; Lee KA; Kim HS
    Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
    Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia Is an Indicator for Worse Organ Damage Trajectories in Patients with Systemic Sclerosis: A Retrospective Study.
    Li Z; Xu D; Jiang X; Li T; Su Y; Mu R
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial design in scleroderma: where are we and where do we go next?
    Chung L; Denton CP; Distler O; Furst DE; Khanna D; Merkel PA;
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S97-102. PubMed ID: 22691217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
    Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
    Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
    Baron M; Hudson M; Steele R; Lo E;
    J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma.
    Low AHL; Ng SA; Berrocal V; Brennan B; Chan G; Ng SC; Khanna D
    Int J Rheum Dis; 2019 Jun; 22(6):1036-1040. PubMed ID: 30838791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term organ damage accrual and late mortality in systemic sclerosis.
    Lazzaroni MG; Moschetti L; Breda M; Franceschini F; Airò P
    Clin Exp Rheumatol; 2023 Oct; ():. PubMed ID: 37933549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study.
    Valenzuela A; Baron M; ; Herrick AL; Proudman S; Stevens W; ; Rodriguez-Reyna TS; Vacca A; Medsger TA; Hinchcliff M; Hsu V; Wu JY; Fiorentino D; Chung L
    Semin Arthritis Rheum; 2016 Dec; 46(3):344-349. PubMed ID: 27371996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.
    Pauling JD; Frech TM; Hughes M; Gordon JK; Domsic RT; Anderson ME; Ingegnoli F; McHugh NJ; Johnson SR; Hudson M; Boin F; Ong VH; Matucci-Cerinic M; Altorok N; Scolnik M; Nikpour M; Shah A; Pope JE; Khanna D; Herrick AL
    J Scleroderma Relat Disord; 2018 Oct; 3(3):249-252. PubMed ID: 30705970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a provisional core set of response measures for clinical trials of systemic sclerosis.
    Khanna D; Lovell DJ; Giannini E; Clements PJ; Merkel PA; Seibold JR; Matucci-Cerinic M; Denton CP; Mayes MD; Steen VD; Varga J; Furst DE;
    Ann Rheum Dis; 2008 May; 67(5):703-9. PubMed ID: 17893248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society.
    Taş YM; Derviş Hakim G; Keskinoğlu P; Kenar G; Yarkan H; Zengin B; Can G; Önen F; Akkoç N; Birlik M; Akarsu M
    Turk J Gastroenterol; 2019 Mar; 30(3):234-241. PubMed ID: 30541712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Khanna D; Furst DE; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Hays RD
    J Rheumatol; 2011 Sep; 38(9):1920-4. PubMed ID: 21724699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch.
    Meijs J; Pors D; Vliet Vlieland TP; Huizinga TW; Schouffoer AA
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-41-8. PubMed ID: 24984228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Khanna D; Hays RD; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Fathi N; Bechtel A; Furst DE
    Arthritis Rheum; 2009 Sep; 61(9):1257-63. PubMed ID: 19714600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study.
    Hsu VM; Denton CP; Domsic RT; Furst DE; Rischmueller M; Stanislav M; Steen VD; Distler JHW; Korish S; Cooper A; Choi S; Schafer PH; Horan G; Hough DR
    J Rheumatol; 2018 Mar; 45(3):405-410. PubMed ID: 29093152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.
    Bodukam V; Hays RD; Maranian P; Furst DE; Seibold JR; Impens A; Mayes MD; Clements PJ; Khanna D
    Rheumatology (Oxford); 2011 Feb; 50(2):330-4. PubMed ID: 20884655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.